Last 1.45 GBp
Change Today -0.05 / -3.33%
Volume 490.1K
VRP On Other Exchanges
As of 3:56 AM 11/28/14 All times are local (Market data is delayed by at least 15 minutes).

verona pharma plc (VRP) Snapshot

1.50 GBp
Previous Close
1.50 GBp
Day High
1.50 GBp
Day Low
1.45 GBp
52 Week High
01/3/14 - 4.44 GBp
52 Week Low
06/23/14 - 1.05 GBp
Market Cap
Average Volume 10 Days
-0.0060 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for VERONA PHARMA PLC (VRP)

Related News

No related news articles were found.

verona pharma plc (VRP) Related Businessweek News

No Related Businessweek News Found

verona pharma plc (VRP) Details

Verona Pharma plc, a biotechnology company, is engaged in the research, discovery, and development of therapeutic drugs in the United Kingdom and Canada. The company develops drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma, allergic rhinitis (hay fever), and cough. Its lead drug compound include RPL554, a bronchodilator/anti-inflammatory drug that has completed Phase I and II clinical trials to treat asthma and COPD. The company is also developing VRP700, an anti-tussive drug, which has Phase II clinical trial for the treatment of cough, as well as novel anti-inflammatory polysaccharides (NAIPs) that in the basic research phase to treat respiratory and inflammatory diseases. The company is based in London, the United Kingdom.

10 Employees
Last Reported Date: 07/3/14

verona pharma plc (VRP) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 330.4K GBP
Executive Director and Member of Audit Commit...
Total Annual Compensation: 42.0K GBP
Compensation as of Fiscal Year 2013.

verona pharma plc (VRP) Key Developments

Verona Pharma plc Announces Executive Changes, Effective Dec. 1, 2014

Verona Pharma plc announced the appointment of David Raymond Ebsworth as Non-Executive Chairman of the Board of Directors with effect from December 1. Ebsworth will succeed Clive Page, who has held the role since founding the company in 2006. Ebsworth has been involved in successful product approvals in the US and Europe. From October 2009 to August 2014, Ebsworth served as Chief Executive Officer of Vifor Pharma. He was also named as CEO of Galenica AG in 2011. Ebsworth had worked for over 19 years in Bayer AG.

Verona Pharma plc Presents at Boston Biotech NY/NJ CEO Conference, Nov-12-2014 11:25 AM

Verona Pharma plc Presents at Boston Biotech NY/NJ CEO Conference, Nov-12-2014 11:25 AM. Venue: Apella, 450 East 29th Street, New York, New York, United States. Speakers: Jan Anders Karlsson.

Verona Pharma plc announces Management Changes

Verona Pharma plc announced that it has appointed Biresh Roy as chief financial officer and member of the board of directors with immediate effect. He takes over from Richard Bungay whose appointment was part-time and a non-board role. During this time he also acted as chief financial officer for several companies, including Enigma diagnostics, Xytis, Morphochem and Santhera.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRP:LN 1.45 GBp -0.05

VRP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VRP.
View Industry Companies

Industry Analysis


Industry Average

Valuation VRP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 0.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERONA PHARMA PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at